Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
Next revision Both sides next revision
covid:unpublished [2020/07/02 16:05]
biogridadmin
covid:unpublished [2020/08/05 13:15]
biogridadmin
Line 5: Line 5:
  
 **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/​health-related behavior, or be reported in news media as established information. **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/​health-related behavior, or be reported in news media as established information.
-  + 
-^  Custom ID  ^  DOI  ^  ​Author ​ ​^ ​Dataset ​ ^ +^  Custom ID  ^  DOI  ^  ​AUTHOR ​ ​^ ​DATASET ​ ^
-|  **888800000001** ​ |  **[[https://​doi.org/​10.1101/​2020.03.22.002386|10.1101/​2020.03.22.002386]]** ​ |  Gordon DE (2020) ​ | **[[https://​thebiogrid.org/​220839/​publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** ​ |+
 |  **888800000002** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.20041962|10.1101/​2020.03.29.20041962]]** ​ |  Gao T (2020) ​ | **[[https://​thebiogrid.org/​221112/​publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** ​ | |  **888800000002** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.20041962|10.1101/​2020.03.29.20041962]]** ​ |  Gao T (2020) ​ | **[[https://​thebiogrid.org/​221112/​publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** ​ |
 |  **888800000003** ​ |  **[[https://​doi.org/​10.1101/​2020.02.16.951723|10.1101/​2020.02.16.951723]]** ​ |  Sun C (2020) ​ | **[[https://​thebiogrid.org/​221178/​publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** ​ | |  **888800000003** ​ |  **[[https://​doi.org/​10.1101/​2020.02.16.951723|10.1101/​2020.02.16.951723]]** ​ |  Sun C (2020) ​ | **[[https://​thebiogrid.org/​221178/​publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** ​ |
Line 13: Line 12:
 |  **888800000005** ​ |  **[[https://​doi.org/​10.1101/​2020.03.14.988345|10.1101/​2020.03.14.988345]]** ​ |  Wang K (2020) ​ | **[[https://​thebiogrid.org/​221183/​publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** ​ | |  **888800000005** ​ |  **[[https://​doi.org/​10.1101/​2020.03.14.988345|10.1101/​2020.03.14.988345]]** ​ |  Wang K (2020) ​ | **[[https://​thebiogrid.org/​221183/​publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** ​ |
 |  **888800000006** ​ |  **[[https://​doi.org/​10.1101/​2020.02.17.951848|10.1101/​2020.02.17.951848]]** ​ |  Zhou Q (2020) ​ | **[[https://​thebiogrid.org/​221185/​publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** ​ | |  **888800000006** ​ |  **[[https://​doi.org/​10.1101/​2020.02.17.951848|10.1101/​2020.02.17.951848]]** ​ |  Zhou Q (2020) ​ | **[[https://​thebiogrid.org/​221185/​publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** ​ |
 +|  **888800000007** ​ |  **[[https://​doi.org/​10.1101/​2020.02.26.964882|10.1101/​2020.02.26.964882]]** ​ |  Jin Z (2020) ​ | **[[https://​thebiogrid.org/​221186/​publication|Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]]]** ​ |
 |  **888800000008** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.013490|10.1101/​2020.03.29.013490]]** ​ |  Wang C (2020) ​ | **[[https://​thebiogrid.org/​221195/​publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** ​ | |  **888800000008** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.013490|10.1101/​2020.03.29.013490]]** ​ |  Wang C (2020) ​ | **[[https://​thebiogrid.org/​221195/​publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** ​ |
 |  **888800000009** ​ |  **[[https://​doi.org/​10.1101/​2020.03.25.996348|10.1101/​2020.03.25.996348]]** ​ |  Dai W (2020) ​ | **[[https://​thebiogrid.org/​221196/​publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** ​ | |  **888800000009** ​ |  **[[https://​doi.org/​10.1101/​2020.03.25.996348|10.1101/​2020.03.25.996348]]** ​ |  Dai W (2020) ​ | **[[https://​thebiogrid.org/​221196/​publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** ​ |
Line 19: Line 19:
 |  **888800000012** ​ |  **[[https://​doi.org/​10.1101/​2020.03.31.019216|10.1101/​2020.03.31.019216]]** ​ |  Liang Q (2020) ​ | **[[https://​thebiogrid.org/​221199/​publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** ​ | |  **888800000012** ​ |  **[[https://​doi.org/​10.1101/​2020.03.31.019216|10.1101/​2020.03.31.019216]]** ​ |  Liang Q (2020) ​ | **[[https://​thebiogrid.org/​221199/​publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** ​ |
 |  **888800000013** ​ |  **[[https://​doi.org/​10.1101/​2020.04.15.042085|10.1101/​2020.04.15.042085]]** ​ |  Bestle D (2020) ​ | **[[https://​thebiogrid.org/​221402/​publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** ​ | |  **888800000013** ​ |  **[[https://​doi.org/​10.1101/​2020.04.15.042085|10.1101/​2020.04.15.042085]]** ​ |  Bestle D (2020) ​ | **[[https://​thebiogrid.org/​221402/​publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** ​ |
-|  **888800000014** ​ |  **[[https://​doi.org/​10.1101/​2020.04.09.033233|10.1101/​2020.04.09.033233]]** ​ |  Jin Z (2020) ​ | **[[https://​thebiogrid.org/​221403/​publication|Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug]]** ​ | 
-|  **888800000015** ​ |  **[[https://​doi.org/​10.1101/​2020.04.08.032763|10.1101/​2020.04.08.032763]]** ​ |  Yin W (2020) ​ | **[[https://​thebiogrid.org/​221404/​publication|Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir]]** ​ | 
 |  **888800000016** ​ |  **[[https://​doi.org/​10.1101/​2020.04.14.042010|10.1101/​2020.04.14.042010]]** ​ |  Chi X (2020) ​ | **[[https://​thebiogrid.org/​221405/​publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** ​ | |  **888800000016** ​ |  **[[https://​doi.org/​10.1101/​2020.04.14.042010|10.1101/​2020.04.14.042010]]** ​ |  Chi X (2020) ​ | **[[https://​thebiogrid.org/​221405/​publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** ​ |
 |  **888800000017** ​ |  **[[https://​doi.org/​10.1101/​2020.04.06.20055475|10.1101/​2020.04.06.20055475]]** ​ |  Ye L (2020) ​ | **[[https://​thebiogrid.org/​221565/​publication|Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor]]** ​ | |  **888800000017** ​ |  **[[https://​doi.org/​10.1101/​2020.04.06.20055475|10.1101/​2020.04.06.20055475]]** ​ |  Ye L (2020) ​ | **[[https://​thebiogrid.org/​221565/​publication|Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor]]** ​ |
Line 40: Line 38:
 |  **888800000033** ​ |  **[[https://​doi.org/​10.1101/​2020.05.01.20077743|10.1101/​2020.05.01.20077743]]** ​ |  Wu Y (2020) ​ | **[[https://​thebiogrid.org/​221836/​publication|A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2]]** ​ | |  **888800000033** ​ |  **[[https://​doi.org/​10.1101/​2020.05.01.20077743|10.1101/​2020.05.01.20077743]]** ​ |  Wu Y (2020) ​ | **[[https://​thebiogrid.org/​221836/​publication|A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2]]** ​ |
 |  **888800000034** ​ |  **[[https://​doi.org/​10.1101/​2020.05.03.074914|10.1101/​2020.05.03.074914]]** ​ |  Liu X (2020) ​ | **[[https://​thebiogrid.org/​221959/​publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** ​ | |  **888800000034** ​ |  **[[https://​doi.org/​10.1101/​2020.05.03.074914|10.1101/​2020.05.03.074914]]** ​ |  Liu X (2020) ​ | **[[https://​thebiogrid.org/​221959/​publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** ​ |
 +|  **888800000035** ​ |  **[[https://​doi.org/​10.1101/​2020.05.21.109157|10.1101/​2020.05.21.109157]]** ​ |  Lui I (2020) ​ | **[[https://​thebiogrid.org/​222215/​publication|Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity]]** ​ |
 +|  **888800000036** ​ |  **[[https://​doi.org/​10.1101/​2020.05.21.107870|10.1101/​2020.05.21.107870]]** ​ |  Partridge LJ (2020) ​ | **[[https://​thebiogrid.org/​222216/​publication|Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line]]** ​ |
 +|  **888800000037** ​ |  **[[https://​doi.org/​10.1101/​2020.05.13.092478|10.1101/​2020.05.13.092478]]** ​ |  Chiodo F (2020) ​ | **[[https://​thebiogrid.org/​222217/​publication|Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota]]** ​ |
 +|  **888800000038** ​ |  **[[https://​doi.org/​10.1101/​2020.05.12.091298|10.1101/​2020.05.12.091298]]** ​ |  Seydoux E (2020) ​ | **[[https://​thebiogrid.org/​222218/​publication|Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual]]** ​ |
 +|  **888800000039** ​ |  **[[https://​doi.org/​10.1101/​2020.05.21.107565|10.1101/​2020.05.21.107565]]** ​ |  Zang J (2020) ​ | **[[https://​thebiogrid.org/​222219/​publication|Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement]]** ​ |
 +|  **888800000040** ​ |  **[[https://​doi.org/​10.1101/​2020.05.12.092171|10.1101/​2020.05.12.092171]]** ​ |  Zhou X (2020) ​ | **[[https://​thebiogrid.org/​222220/​publication|Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation]]** ​ |
 +|  **888800000041** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.156455|10.1101/​2020.06.17.156455]]** ​ |  Stukalov A (2020) ​ | **[[https://​thebiogrid.org/​222410/​publication|Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV]]** ​ |
 +|  **888800000042** ​ |  **[[https://​doi.org/​10.1101/​2020.06.05.135921|10.1101/​2020.06.05.135921]]** ​ |  Bertoglio F (2020) ​ | **[[https://​thebiogrid.org/​222602/​publication|SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface]]** ​ |
 +|  **888800000043** ​ |  **[[https://​doi.org/​10.1101/​2020.06.05.135699|10.1101/​2020.06.05.135699]]** ​ |  Moustaqil M (2020) ​ | **[[https://​thebiogrid.org/​222603/​publication|SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.]]** ​ |
 +|  **888800000044** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.157982|10.1101/​2020.06.17.157982]]** ​ |  Starr TN (2020) ​ | **[[https://​thebiogrid.org/​222652/​publication|Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding]]** ​ |
 +|  **888800000045** ​ |  **[[https://​doi.org/​10.1101/​2020.06.05.134114|10.1101/​2020.06.05.134114]]** ​ |  Daly JL (2020) ​ | **[[https://​thebiogrid.org/​222653/​publication|Neuropilin-1 is a host factor for SARS-CoV-2 infection]]** ​ |
 +|  **888800000046** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.158121|10.1101/​2020.06.17.158121]]** ​ |  Cubuk J (2020) ​ | **[[https://​thebiogrid.org/​222654/​publication|The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA]]** ​ |
 +|  **888800000047** ​ |  **[[https://​doi.org/​10.1101/​2020.06.09.142794|10.1101/​2020.06.09.142794]]** ​ |  Yang Y (2020) ​ | **[[https://​thebiogrid.org/​222655/​publication|The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.]]** ​ |
 +|  **888800000048** ​ |  **[[https://​doi.org/​10.1101/​2020.06.02.130161|10.1101/​2020.06.02.130161]]** ​ |  Hanke L (2020) ​ | **[[https://​thebiogrid.org/​222656/​publication|An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction]]** ​ |
 +|  **888800000049** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.156471|10.1101/​2020.06.17.156471]]** ​ |  Conceicao C (2020) ​ | **[[https://​thebiogrid.org/​222704/​publication|The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins]]** ​ |
 +|  **888800000050** ​ |  **[[https://​doi.org/​10.1101/​2020.06.07.138677|10.1101/​2020.06.07.138677]]** ​ |  Luan X (2020) ​ | **[[https://​thebiogrid.org/​222705/​publication|Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376]]** ​ |
 +|  **888800000051** ​ |  **[[https://​doi.org/​10.1101/​2020.06.02.129098|10.1101/​2020.06.02.129098]]** ​ |  Lv Z (2020) ​ | **[[https://​thebiogrid.org/​222706/​publication|Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody]]** ​ |
 +|  **888800000052** ​ |  **[[https://​doi.org/​10.1101/​2020.06.06.137513|10.1101/​2020.06.06.137513]]** ​ |  Lou Y (2020) ​ | **[[https://​thebiogrid.org/​222707/​publication|Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries]]** ​ |
 +|  **888800000053** ​ |  **[[https://​doi.org/​10.1101/​2020.05.27.118117|10.1101/​2020.05.27.118117]]** ​ |  Douangamath A (2020) ​ | **[[https://​thebiogrid.org/​222708/​publication|Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease]]** ​ |
 +|  **888800000054** ​ |  **[[https://​doi.org/​10.1101/​2020.06.16.155812|10.1101/​2020.06.16.155812]]** ​ |  Li J (2020) ​ | **[[https://​thebiogrid.org/​222709/​publication|Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin]]** ​ |
 +|  **888800000055** ​ |  **[[https://​doi.org/​10.1101/​2020.06.15.153387|10.1101/​2020.06.15.153387]]** ​ |  Beddingfield B (2020) ​ | **[[https://​thebiogrid.org/​222710/​publication|The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection]]** ​ |
 
covid/unpublished.txt · Last modified: 2021/04/24 15:17 by biogridadmin